• patients
  • Eight patients had co-occurring haematological diseases. (bmj.com)
  • Results Nine patients (seven with haematological diseases) responded to rituximab: six of them, who were non-responders to conventional therapies, improved clinically, and the other three maintained the improvement that they usually achieved with intravenous immunoglobulin or plasma exchange. (bmj.com)